Sogue Coulibaly

Title: Sogue Coulibaly: Innovator in Poxvirus Research

Introduction

Sogue Coulibaly is a notable inventor based in Vienna, Austria. He has made significant contributions to the field of virology, particularly in the development of modified poxviruses. With a total of 2 patents, his work focuses on innovative vaccine technologies.

Latest Patents

Coulibaly's latest patents include groundbreaking inventions related to modified poxviruses. One of his key inventions is a modified smallpox virus vaccine based on a recombinant drug-sensitive vaccinia virus. This invention provides recombinant poxviruses that contain an integrated exogenous sequence, such as a foreign gene, encoding a prodrug converting polypeptide. This polypeptide can convert a prodrug to a drug that prevents virus replication or is otherwise toxic to the virus. The recombinant poxviruses can be suitable for use as vaccines. Additionally, the invention outlines methods of inhibiting virus replication, methods of vaccination, and methods of treating vaccinated subjects showing signs or otherwise at risk for vaccination-induced disease.

Career Highlights

Throughout his career, Sogue Coulibaly has worked with prominent companies in the healthcare sector, including Baxter International Inc. and Baxter Healthcare SA. His experience in these organizations has contributed to his expertise in vaccine development and virology.

Collaborations

Coulibaly has collaborated with notable professionals in his field, including Falko-Guenter Falkner and Georg Holzer. These collaborations have further enhanced his research and innovation capabilities.

Conclusion

Sogue Coulibaly is a distinguished inventor whose work in modified poxviruses has the potential to revolutionize vaccine development. His contributions to virology and collaboration with industry leaders underscore his importance in the field.